Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akebia, Astrazeneca, Beigene, Chiesi, Daiichi Sankyo, Incyte, Janssen, Merck, Protalix, Regeneron, Ridgeback, Servier, Sobi, Timber.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aslan, Astria, Atea, Biocryst, Codexis, Fulcrum, Innocare, Keymed, Merck, Nektar, Nestlé, Orchard, Oscotec, Prilenia, Regenxbio, Tvardi, Werewolf.

Global Health Drug Discovery Institute (GHDDI) has presented 3C-like proteinase (3CLpro) (SARS-CoV-2) inhibitors reported to be useful for the treatment of Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV) and SARS-CoV-2 infections (COVID-19).

Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D Molecular, Accutar, Amicus, Astellas, Cantargia, Denali, Forge, Horizon, Janssen, Pharmaessentia, Regenxbio, Sangamo, Skye, Theratechnologies, Viiv.

Researchers from PDS Biotechnology Corp. and affiliated organizations have detailed the development and preclinical evaluation of recombinant protein vaccines formulated with enantio-specific cationic lipid R-DOTAP.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Adial, Alimera, Cognition, Erydel, Fapon, GSK, Pfizer, PTC, Sage, Seagen, Viiv, Vir.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alteogen, Biomx, Corium, Dare, Grid, Immunic, Immunocore, Jaguar, Kinnate, Linkinvax, Merck & Co., Modus, Shionogi.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: ABVC, Akebia, Alnylam, Arcutis, Azafaros, Beckley, Biohaven, Biosyngen, Chemomab, Cincor, GC, Icosavax, Kadimastem, Mezzion, Optinose, Orasis, Pfizer, Regeneron, RVAC, Sinovac, Valneva, Vaxcyte.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Actinium, Aileron, Akari, Ascletis, BMS, Bridge, Effector, Gamida, Ionis, Junshi, Kinarus, Medivir, Merck & Co., Neurophth, Palvella, Pharming, Photocure, Scancell, Takeda, Telix, Westvac.